Search clinical trials for: Sorafenib (BAY43-9006)

Total 1119 results

Bayer

Completed

Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients (HATT)

Hepatocellular Carcinoma

Taiwan
Bayer

Terminated

Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment (SORAGO-HCC)

Hepatocellular Carcinoma

Germany
Bayer

Terminated

A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.

Carcinoma, Renal Cell

Italy, Spain, France, Austria, Poland, United Kingdom, Ireland
Bayer

Completed

Relative Bioavailability of Sorafenib Tablet for Oral Suspension

Biological Availability

Germany
Bayer

Completed

An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib (ROCURS)

Coronavirus Disease 2019 (COVID-19) | SARS-CoV-2 Infection | Malignant Solid Tumors

United States
University of Florida

Completed

Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

United States
Bayer

Completed

Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program

Carcinoma, Renal Cell

Japan
Bayer

Completed

Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China (SUCCESS)

Carcinoma, Hepatocellular

China
Bayer

Completed

Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting (NEXST)

Carcinoma, Renal Cell

Poland
Bayer

Completed

Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma

Carcinoma, Renal Cell

United States, Canada
Bayer
Amgen

Completed

BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)

Cancer | Carcinoma, Non-Small Cell Lung

United States, Germany
Bayer

Completed

Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar

Carcinoma, Renal Cell | Carcinoma, Renal Cell (Advanced)

Poland, China, Slovakia, France, Germany, Indonesia, Korea, Republic of, Sweden, Philippines, Austria, Colombia, Czech Republic, Mexico, Russian Federation, Slovenia, Argentina, Greece, Netherlands
Bayer

Completed

Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety (SORINT)

Carcinoma, Hepatocellular

Germany
Bayer

Completed

Regulatory Post Marketing Surveillance Study on Nexavar®

Carcinoma, Renal Cell | Carcinoma, Hepatocellular

Korea, Republic of
Bayer

Completed

Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan

Carcinoma, Hepatocellular

Japan
Bayer

Completed

An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma

Carcinoma, Renal Cell

Belgium, Italy, Spain, Germany, France, Netherlands, Switzerland, Poland, Sweden, United Kingdom, Denmark
Bayer

Terminated

Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.

Carcinoma, Renal Cell

United States
Bayer

Completed

INSIGHT - Post Marketing Surveillance (INSIGHT)

Carcinoma, Hepatocellular

Germany, Austria
Bayer

Completed

Sorafenib Gastric Cancer Asian Phase I Study

Gastric Cancer

Japan
Bayer
Amgen

Completed

Sorafenib/Docetaxel Dose Escalation Trial

Neoplasms

United States
Bayer

Completed

Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib (GIDEON)

Carcinoma, Hepatocellular

Japan, China, Slovakia, Croatia, France, Hungary, Indonesia, Korea, Republic of, Malaysia, Singapore, Spain, Sweden, Thailand, Philippines, Colombia, Czech Republic, Hong Kong, Italy, Kazakhstan, Mexico, Romania, Russian Federation, Ukrain... and more
Bayer

Completed

Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy (STELLA)

Hepatocellular Carcinoma

Italy
Bayer
Onyx Therapeutics, Inc.

Completed

Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination

Neoplasms

Germany, France
Bayer

Completed

A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC). (MISSION)

Carcinoma | Non-Small-Cell Lung

Italy, Spain, China, Korea, Republic of, Bulgaria, Turkey, Greece, Philippines, Taiwan, Russian Federation, Hungary, Singapore, France, Netherlands, Sweden, Belgium, United States, Austria, Thailand, Germany, Israel, Poland, Canada, United... and more
Bayer
Amgen

Completed

Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

Thyroid Neoplasms

France, China, Korea, Republic of, United States, Spain, Russian Federation, United Kingdom, Netherlands, Sweden, Austria, Italy, Bulgaria, Poland, Saudi Arabia, Germany, Japan, Belgium, Denmark
Bayer

Completed

Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan

Carcinoma, Renal Cell

Japan
Bayer

Completed

Sorafenib in Elderly mRCC

Carcinoma, Renal Cell

China
Bayer

Completed

A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).

Carcinoma, Hepatocellular

Belgium, France, Spain, China, Canada, Singapore, United States, Germany, Australia, Austria, Korea, Republic of, Italy, Taiwan
Bayer

Completed

Sorafenib Drug Drug Interaction Study in Healthy Male Subjects

Drug Interactions

Germany
Bayer

Completed

Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer

Ovarian Neoplasms

Poland, Belgium, Spain, Hong Kong, Korea, Republic of, Canada, Italy, Singapore, Germany, United States, Netherlands, France, Japan, Finland
Bayer

Completed

Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec (ORACLE)

Chronic Myelogenous Leukemia

United States, France
Bayer

Completed

A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Carcinoma, Hepatocellular

China, Taiwan, Korea, Republic of
Bayer

Active, not recruiting

Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib (JPMS-DTC)

Thyroid Carcinoma

Japan
Bayer
ICON Clinical Research

Completed

Sorafenib Long Term Extension Program (STEP)

Neoplasms

Spain, Hong Kong, Canada, Germany, France, United States, United Kingdom, Taiwan, New Zealand, Australia, Belgium, China, Bulgaria, Italy, Colombia, Poland, Korea, Republic of, Brazil, Ukraine
Bayer

Completed

Sorafenib for Residue Disease After Resection With Curative Intent (SECURE)

Carcinoma, Hepatocellular

China
Bayer

Completed

Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients

Thyroid Carcinoma

Japan
Bayer

Completed

Sorafenib Dose Escalation in Renal Cell Carcinoma

Carcinoma, Renal Cell

Italy, France, Germany, United Kingdom, Poland
Bayer

Completed

BAY43-9006 Phase II Study for Renal Cell Carcinoma

Carcinoma, Renal Cell

Japan
Bayer

Completed

Extension Program for Bay 43-9006

Metastasis | Neoplasm

Canada, Belgium, Germany, United States
Bayer

Completed

Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients

Neoplasms

United States
Bayer

Completed

Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)

Carcinoma, Renal Cell

China, Taiwan
Bayer

Completed

Long-term Extension From RCC Phase II (11515)

Carcinoma, Renal Cell

Japan
Bayer

Completed

A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ® (PONDIAC)

Carcinoma, Renal Cell | Carcinoma, Renal Cell (Advanced)

Belgium
Bayer

Completed

Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006

Kidney Diseases
Bayer

Completed

Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)

Carcinoma, Hepatocellular

Belgium, China, Hong Kong, Switzerland, Japan, France, Spain, Germany, United States, Austria, Czechia, United Kingdom, Korea, Republic of, Thailand, New Zealand, Hungary, Israel, Italy, Taiwan, Singapore, Turkey
Bayer
Amgen

Completed

Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer

Carcinoma, Renal Cell

Italy, Spain, Canada, United States, Russian Federation, France, Australia, Chile, Germany, Hungary, Israel, United Kingdom, South Africa, Poland, Netherlands, Belgium, Ukraine, Argentina, Brazil
Bayer

Completed

Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin

Cancer

Canada
Bayer
Amgen

Completed

Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer

Carcinoma, Renal Cell

United States, United Kingdom
Bayer

Completed

Hepatic Impairment Study

Liver Disease

United States
Bayer

Completed

Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors

Neoplasms

United States

Search clinical trials for: Sorafenib (BAY43-9006)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations